| Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.J Clin Oncol | PMID 42641116无 PMCID | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.Dermatol Ther (Heidelb) | PMID 42667537PMC13650221 | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.Dig Liver Dis | PMID 42669571无 PMCID | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.Nat Med | PMID 42680950PMC13668648 | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 42705254无 PMCID | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort.ESMO Open | PMID 42727418PMC13583573 | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study.ESMO Open | PMID 42748509PMC13595130 | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Multicenter Randomized Phase III Trial Comparing MET Tyrosine Kinase Inhibitors vs. Immune Checkpoint Inhibitors With or Without Chemotherapy as First-Line Treatment for Patients With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutations: JCOG2506 (DECIDE-MET).Clin Lung Cancer | PMID 42753422无 PMCID | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial.ESMO Open | PMID 42785163PMC13634523 | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.ESMO Open | PMID 42815410PMC13654028 | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.Lancet Haematol | PMID 42822478无 PMCID | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T-cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized-controlled trial.Hemasphere | PMID 42824995PMC13628557 | 2026-Oct | 0.98 | Eligible: explicit Phase 3 randomized trial in human malignant neoplasm with a drug-containing intervention and primary time-to-event endpoint (EFS), reporting original results. | 待处理 |
| Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research.J Transl Int Med | PMID 42974517PMC13726654 | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial.Future Oncol | PMID 42990047PMC13757690 | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Envonalkib Versus Crizotinib in Treatment-Naive ALK-Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study.MedComm (2020) | PMID 42830869PMC13634175 | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial.EClinicalMedicine | PMID 42898854PMC13679299 | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.Nat Med | PMID 42816596无 PMCID | 2026-Sep-30 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.Transl Cancer Res | PMID 42870825PMC13657816 | 2026-Sep-30 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Population Pharmacokinetics and Exposure-response Analysis of Durvalumab in Patients with Limited-stage Small-cell Lung Cancer in the Phase 3 ADRIATIC Study.AAPS J | PMID 42806195无 PMCID | 2026-Sep-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study.Adv Ther | PMID 42782448无 PMCID | 2026-Sep-24 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.Br J Haematol | PMID 42770812无 PMCID | 2026-Sep-22 | 0.98 | Eligible Phase III randomized oncology drug trial reporting PFS time-to-event results. | 待处理 |
| An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial.medRxiv | PMID 42779818PMC13596521 | 2026-Sep-22 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.Signal Transduct Target Ther | PMID 42764281PMC13590641 | 2026-Sep-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.Lancet | PMID 42716074无 PMCID | 2026-Sep-19 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.N Engl J Med | PMID 42748428无 PMCID | 2026-Sep-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of immune checkpoint inhibitors in female patients with cancer: a systematic review and meta-analysis.Sci China Life Sci | PMID 42752777无 PMCID | 2026-Sep-15 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.Med | PMID 42600610无 PMCID | 2026-Sep-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.J Clin Oncol | PMID 42585631PMC13557475 | 2026-Sep-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Conversion hepatectomy for unresectable hepatocellular carcinoma: Principles of patient selection and surgical decision-making.Biosci Trends | PMID 42716789无 PMCID | 2026-Sep-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Response-Adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase II Trial.Clin Cancer Res | PMID 42717678无 PMCID | 2026-Sep-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.J Natl Cancer Inst | PMID 42720590无 PMCID | 2026-Sep-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study.Clin Cancer Res | PMID 42714840无 PMCID | 2026-Sep-09 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Preventive effect of goshajinkigan on paclitaxel-induced peripheral neuropathy: an open-label, randomized phase II study (OLCSG2101).Oncologist | PMID 42750137PMC13612169 | 2026-Sep-09 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.JAMA | PMID 42574006PMC13458949 | 2026-Sep-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.Haematologica | PMID 42687805无 PMCID | 2026-Sep-03 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Clinical outcomes by type of surgery with perioperative durvalumab in patients with resectable non-small cell lung cancer.J Thorac Cardiovasc Surg | PMID 42692248无 PMCID | 2026-Sep-03 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306).Nat Commun | PMID 42834033PMC13639055 | 2026-Sep-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.Signal Transduct Target Ther | PMID 42675036PMC13530150 | 2026-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.ESMO Gastrointest Oncol | PMID 42583212PMC13459562 | 2026-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.J Comp Eff Res | PMID 42583940PMC13556922 | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).Ann Oncol | PMID 42613139PMC13488494 | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Paclitaxel oral solution versus paclitaxel injection as second-line therapy for advanced gastric cancer: a multicenter, open-label, randomized phase III trial.ESMO Open | PMID 42617423PMC13520883 | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.Lancet Oncol | PMID 42633754无 PMCID | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.Lancet Oncol | PMID 42636832无 PMCID | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.Lancet Oncol | PMID 42636833无 PMCID | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.Lancet Oncol | PMID 42636834无 PMCID | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.Future Oncol | PMID 42682104PMC13750221 | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer.Ann Thorac Surg Short Rep | PMID 42719123PMC13555408 | 2026-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.Target Oncol | PMID 42762393PMC13631018 | 2026-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| HER1-HER4 expression and co-expression in advanced urothelial carcinoma.ESMO Open | PMID 42785914PMC13650353 | 2026-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |